Friday, July 10, 2026

Drug profile · INN

polyestradiol phosphate

polyestradiol phosphate (ESTRADURIN) is a estrogen receptor alpha agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — polyestradiol phosphate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

polyestradiol phosphate (ESTRADURIN) is a estrogen receptor alpha agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN polyestradiol phosphate
Brand ESTRADURIN
Mechanism Estrogen receptor alpha agonist
Target Estrogen receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Estrogen receptor alpha agonist

Primary target: Estrogen receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. estradiol Estrogen receptor alpha agonist
  2. estradiol valerate Estrogen receptor alpha agonist
  3. estrogens, conjugated synthetic a Estrogen receptor agonist
  4. estropipate Estrogen receptor alpha agonist
  5. ethinyl estradiol Estrogen receptor alpha agonist
  6. fulvestrant Antineoplastic and immunomodulating agents (L02)

Frequently asked questions

What is polyestradiol phosphate?

polyestradiol phosphate (ESTRADURIN) is a estrogen receptor alpha agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for polyestradiol phosphate?

ESTRADURIN is a marketed brand name for polyestradiol phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of polyestradiol phosphate?

polyestradiol phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.